Skip to main content

Table 3 Hematological and organ responses to daratumumab-based regimens

From: Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis

Secondary outcome

Studies (n)

Responses (n)

Patients (n)

Response rate % (95% CI)

I2

Hematologic response

CR

24

193

752

30 (23, 36)

65%

VGPR

23

295

729

40 (33, 46)

61%

PR

18

82

544

17 (14, 21)

50%

ORR

27

633

806

77 (73, 80)

45%

Organ response

Cardiac response

20

166

440

41 (34, 49)

56%

Renal response

18

139

345

43 (32, 54)

69%

  1. CI  confidence interval, CR  complete response, PR  partial response rate, VGPR  very good partial response